



FOR IMMEDIATE RELEASE

# Satisfaction of Listing Conditions

Brisbane, Queensland, 1 April 2022 – Precision microbiome company, Microba Life Sciences Limited (**Microba**) confirms that it has satisfied each of the Conditions to Admission as detailed in the Admission Decision dated 15 March 2022.

Microba provides the following pre-quotation disclosures:

## The issue of Shares and Options

The issue of the following securities:

| Securities      | Detail                                                                   | Number                     |
|-----------------|--------------------------------------------------------------------------|----------------------------|
| Ordinary Shares | The issue of Ordinary Shares under the Prospectus dated 11 February 2022 | 66,666,666 Ordinary Shares |
| Options         | The issue of Director Options with an exercise price of \$0.675          | 1,200,000 Options          |

## Microba's capital deck

The capital deck of Microba is as follows:

| Security        | Number                                                                                                                                                                              |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ordinary Shares | 274,357,998 Ordinary Shares. This is made up of: <ul style="list-style-type: none"><li>• 207,691,332 Existing Shares;</li><li>• 66,666,666 Shares issued under the Offer.</li></ul> |
| Options         | 18,800,000 Options. This is made up of: <ul style="list-style-type: none"><li>• 17,600,000 Existing Options; and</li><li>• 1,200,000 Director Options.</li></ul>                    |



### ASX imposed escrow

The following Shares and Options are subject to ASX restrictions:

| Security        | Number     | ASX restriction period                                                                                                                      |
|-----------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Ordinary Shares | 48,031,314 | Commencing on the date of official quotation of the ordinary shares in Microba ( <b>Quotation</b> )<br>Ending 24 months following Quotation |
| Ordinary Shares | 12,500     | Commencing on 15 June 2021<br>Ending on 15 June 2022                                                                                        |
| Options         | 2,700,000  | Commencing on Quotation<br>Ending 24 months following Quotation                                                                             |

### Voluntary escrow

The following Shares and Options are subject to voluntary escrow:

| Security        | Number     | Voluntary escrow period                                         |
|-----------------|------------|-----------------------------------------------------------------|
| Ordinary Shares | 57,690,639 | Commencing on Quotation<br>Ending 6 months following Quotation  |
| Ordinary Shares | 54,500,297 | Commencing on Quotation<br>Ending on 27 January 2024            |
| Ordinary Shares | 140,000    | Commencing on 11 November 2021<br>Ending on 11 November 2024    |
| Options         | 8,250,000  | Commencing on 5 February 2022<br>Ending on 5 February 2024      |
| Options         | 7,850,000  | Commencing on Quotation<br>Ending 12 months following Quotation |

### ASX waiver

On 15 March 2022, the ASX granted Microba a waiver from listing rule 1.1 condition 12 to the extent necessary to permit Microba to have on issue, 7,850,000 Existing Options (Incentive Options) with an exercise price of less than \$0.20.

Authorised for release by the Board of Microba Life Sciences Limited.

## About Microba Life Sciences Limited

Microba Life Sciences Limited is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut



microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: [www.microba.com](http://www.microba.com)

**For further information, please contact:**

Peter Webse

Joint Company Secretary

T: +61 409 328 199

E: [Peter.Webse@microba.com](mailto:Peter.Webse@microba.com)